ALSO NOTED: Genta places notes;Vaccine research blasts off; and much more...

> Genta announced that it has struck definitive agreements with investors to place senior secured convertible notes due in 2010 totaling in aggregate up to $40 million in gross proceeds before fees and expenses. Release

> A Lehman Brothers analyst is bullish on Regeneron's cancer drug aflibercept, saying it compares well to Avastin. That opinion came after investors shaved 20 percent off the value of Regeneron shares after seeing disappointing data for ovarian cancer. Report

> The biotech start-up Iatrica is moving into new space at the John G. Rangos Building in East Baltimore. The building opened in April. Story

> Sangamo BioSciences has completed patient enrollment into its Phase II clinical trial in subjects with moderate to severe diabetic neuropathy. Release

> Topical applications of a naturally occurring fat molecule have the potential to slow down skin aging, whether through natural causes or damage, researchers report. Release

And Finally... Vaccine research is heading to outer space. Report

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.